Health Bulletin 15/July/2026

The Youth Congress on Tuesday staged a protest in Ballari, Karnataka, demanding the resignation of Union Education Minister Dharmendra Pradhan over the alleged NEET question paper leak. Organised under the 'Chhatron Ki Goonj' campaign, the protest accused the Centre and the National Testing Agency (NTA) of failing to conduct a fair and transparent examination, leaving lakhs of students under stress and uncertainty.

Addressing the gathering, Karnataka Youth Congress president Manjunath Gowda alleged that the BJP criticised minor issues in Karnataka's Common Entrance Test (CET) but remained silent on the alleged NEET paper leak, calling it a case of "double standards." He demanded a comprehensive inquiry into the functioning of the NTA, greater transparency in the examination system, and urged the Centre to strengthen the role of state-level CETs. The demonstration was led by Ballari District Youth Congress leaders, including K Srikanth, NKS Manjunath, and Vivek Mandimath, reports Deccan Chronicle.

FMGE June 2026: NBE to Distribute Pass Certificates From July 22

The National Board of Examinations in Medical Sciences (NBEMS) has announced the schedule for distributing the Foreign Medical Graduate Examination (FMGE) Screening Test Pass Certificates for the June 2026 session.

NBE to distribute FMGE June 2026 pass certificates from July 22, details

Medical Admission Fraud Alert: JIPMER Advises Students to Beware of Touts

JIPMER warns against medical admission fraud, says no one can secure seats outside official process

Oxford, Serum Institute Launch Human Trials of Vaccine Against Bundibugyo Ebola Strain

The University of Oxford and the Serum Institute of India (SII) have launched the world's first human trial of a vaccine against the Bundibugyo strain of the Ebola virus, for which no approved vaccine currently exists. The Phase I trial will include 50 healthy volunteers aged 18–55 in Oxford to evaluate the vaccine's safety and its ability to trigger an immune response. The vaccine, called ChAdOx1 BDBV, has been developed using the same viral vector platform as the Oxford-AstraZeneca COVID-19 vaccine. The trial was launched just 57 days after the latest Bundibugyo Ebola outbreak was declared, according to an NDTV report.

The Serum Institute of India has supplied 4,000 investigational doses for the trial and is preparing for large-scale manufacturing if the vaccine proves successful. If the Phase I study shows positive results, the vaccine will move to larger clinical trials before regulatory approval is considered. Researchers believe the vaccine could help control future Ebola outbreaks, while Oxford and Serum Institute of India have pledged to ensure rapid and affordable access for affected countries if the vaccine is approved.